COVID-19 Response (VI): STAGE 2 Oral DNA Vaccine Development
$4,571,774.00
Grant Value
2021-22
Fiscal Year
Description
This project will involve further development and characterization of oral bacTRL-based vaccines. This work includes the preclinical development of additional bacTRL-based products including emergent or predicted SARS-CoV-2 variants, as well as the continued evaluation of the lead vaccine candidate in a Phase I clinical trial.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Grant Details
Recipient
Symvivo Corporation
Operating as: Alexander Graves
Location
Burnaby, BC V5J 5J8
Agreement Details
Number: 974484
Reference: 172-2021-2022-Q1-974484
Timeline
Start: June 1, 2021
End: March 18, 2022
Program
Industrial Research Assistance Program Contributions to Firms
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or …
Sector
Professional, scientific and technical services (541710)
Your Contribution
Calculate how much you personally contributed to this grant through your taxes.
Calculate My Share